Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Investors Rally Behind Eisai as Pharma Shares Surge on Positive Pipeline & FDA Breakthrough Designations

Explore how Eisai’s diversified portfolio and breakthrough trials are boosting investor confidence, with highlights on Alzheimer’s, oncology and neuroinflammation research.

Dr. Michael Chen

01/01/2026, 00:43

4 minutes to read

How Bayer’s 2025 Surge, Cytokinetics Deal, and Glyphosate Lawsuits Shape Its 2026 Outlook

Explore Bayer AG’s 2025 surge, Cytokinetics partnership, glyphosate litigation and Monsanto integration – what fuels 2026 growth?

Dr. Michael Chen

31/12/2025, 15:07

4 minutes to read

Hengrui Accelerates SHR6508 & PALI Development After NMPA Trial Approval

Hengrui’s new licensing deals for SHR6508 and PALI, combined with NMPA approval for a pivotal trial, set the stage for rapid progress in CNS and bone‑health therapeutics.

Dr. Michael Chen

29/12/2025, 18:33

4 minutes to read

Haleon PLC Holds Steady Amid OTC R&D: Investors Watch Emerging Data & Market Trends

Haleon PLC’s OTC portfolio shows price stability amid scientific R&D; investors watch clinical trials and regulatory updates on oral‑care, vitamins, and pain relief.

Dr. Michael Chen

28/12/2025, 17:12

5 minutes to read

Novo Nordisk Shares Surge as FDA Approves Oral Wegovy, Boosting Obesity‑Care Momentum

New oral Wegovy approval lifts Novo Nordisk shares, boosting its weight‑loss pipeline and investor confidence in a growing obesity‑drug market.

Dr. Michael Chen

28/12/2025, 07:25

4 minutes to read

Thermo Fisher Announces Q1 2026 Earnings Call: What Investors Should Expect

Thermo Fisher’s Q1 2026 earnings call will reveal how its leading PCR, NGS and live‑cell imaging platforms drive revenue and support drug discovery and regulatory success.

Dr. Michael Chen

28/12/2025, 05:32

4 minutes to read

Novo Nordisk Shares Surge as FDA Approves Oral Wegovy for Weight Loss

New FDA approval of oral Wegovy boosts Novo Nordisk shares, showing comparable weight‑loss results to injections with better convenience.

Dr. Michael Chen

26/12/2025, 16:35

4 minutes to read

Shionogi Expands ALS R&D & Secures RADICAVA® Rights to Boost Global Portfolio

Shionogi expands ALS R&D and global reach, partnering with Salubritas and securing Radicava® rights—boosting science, market share, and investor confidence.

Dr. Michael Chen

26/12/2025, 00:13

3 minutes to read

Sanofi’s $2.2 B Dynavax Deal Boosts Vaccine Reach While Tolebrutinib Faces FDA Hurdle

Sanofi’s $2.2 billion Dynavax deal boosts its U.S. vaccine lineup, adding hepatitis‑B and shingles candidates, while an FDA CRL on tolebrutinib shows regulatory hurdles for its MS therapy.

Dr. Michael Chen

25/12/2025, 12:09

4 minutes to read

Thermo Fisher Surges on Q2 Earnings, Boosting Single‑Use Bioprocessing Growth

Thermo Fisher Scientific tops earnings expectations, boosting shares as its single‑use bioprocessing line and clinical‑trial tools drive growth in cell‑ and gene‑therapy markets.

Dr. Michael Chen

25/12/2025, 03:53

3 minutes to read